H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the shares. Arcturus on Thursday announced that interim ...
Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst expectations. Their annual revenue took a dip, dropping $14.5 million from the ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback